Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Chemotherapy and Immune Therapy Combined With Lactobacillus Johnsonii in Patients With Metastatic or Locally Advanced Unresectable or Recurrent EGFR/ALK Wild-type Adenocarcinoma Non-small Cell Lung Cancer (NSCLC), PD-L1 Positive (CPS≥1) Triple-negative Breast Cancer (TNBC) and HER2-negative Gastric or Gastro-oesophageal Junction Adenocarcinoma: a Multicenter, Randomized, Double-blind, Clinical Trial.

NCT07191405 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.

NCT NCT07191405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07191405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Chemotherapy and Immune Therapy Combined With Lactobacillus Johnsonii in Patients With Metastatic or Locally Advanced Unresectable or Recurrent EGFR/ALK Wild-type Adenocarcinoma Non-small Cell Lung Cancer (NSCLC), PD-L1 Positive (CPS≥1) Triple-negative Breast Cancer (TNBC) and HER2-negative Gastric or Gastro-oesophageal Junction Adenocarcinoma: a Multicenter, Randomized, Double-blind, Clinical Trial.
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 18, 2025
Completion date
December 31, 2026
Enrollment
156 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, immunotherapy